Seeking Alpha

Salix Pharmaceuticals (SLXP +7.3%) shares surge after Q4 results topped expectations and sales...

Salix Pharmaceuticals (SLXP +7.3%) shares surge after Q4 results topped expectations and sales of its Xifaxan gastrointestinal drug picked up significantly during H2 2011. SLXP also guides to at least 25% organic growth in Xifaxan in 2012, with strong growth in January that beat the prior record month of December.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)